Stockscreener 앱 받기
86.82
0.39%
0.34
시간 외 거래:
85.91
-0.91
-1.05%
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Biotech Dianthus to meet investors at Jefferies and Goldman events - Stock Titan
Dianthus (DNTH) director receives 6,090 options vesting by 2027 - Stock Titan
Dianthus Therapeutics (DNTH) director receives grant of 6,090 stock options - Stock Titan
Director at Dianthus Therapeutics (DNTH) granted 6,090 stock options - Stock Titan
Dianthus (DNTH) director Jonathan Violin receives grant of 6,090 stock options - Stock Titan
Director Paula Soteropoulos gets 6,090 DNTH options in new award - Stock Titan
Dianthus (NASDAQ: DNTH) investors approve board, pay and auditor - Stock Titan
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish - AOL.com
Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital Raise - Yahoo Finance
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - sharewise.com
Dianthus Therapeutics CFO sold 8,224 shares worth $739,000. - Pluang
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - The Motley Fool
RA Capital group reports 2,611,733 Dianthus shares (DNTH) - Stock Titan
Point72 reports 643,599 shares (1.2%) in Dianthus Therapeutics (DNTH) - Stock Titan
Sirenia Capital (DNTH) discloses 5.3% stake including 500K options - Stock Titan
Wellington group reports 4.77% stake in Dianthus (NASDAQ: DNTH) - Stock Titan
Tango Therapeutics is the best performing healthcare stock in March - MSN
Octagon entities disclose 1.95M-share stake in Dianthus Therapeutics (DNTH) - Stock Titan
Vanguard Group Inc. Increases Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $65.2 to $200 - Moomoo
TradingKey - TradingKey
Dianthus Therapeutics (DNTH) director exercises options, sells 599 shares under 10b5-1 plan - Stock Titan
Evercore Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $120 - Moomoo
UBS Group AG Acquires 469,547 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Brokerages - MarketBeat
Number of shareholders of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Number of shareholders of Dianthus Therapeutics, Inc. – SWB:87E - TradingView
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
Q2 EPS Forecast for Dianthus Therapeutics Raised by Analyst - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: 47.87% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Raymond James Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $110 - Moomoo
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $125 to $200 - Moomoo
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results - The Manila Times
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates - MSN
MSN Money - MSN
Dianthus Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q1 Revenue $463K, vs. FactSet Est of $404K - marketscreener.com
Dianthus Therapeutics Q1 net loss widens on higher expenses - TradingView
Dianthus Therapeutics (NASDAQ: DNTH) builds $1.1B cash to fund autoimmune pipeline - Stock Titan
Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dianthus got 20 responders before 40 patients in CIDP trial - Stock Titan
Dianthus (Nasdaq: DNTH) raises $719M, ends Q1 2026 with $1.2B cash - Stock Titan
0.98%
0.12%
자본화:
|
볼륨(24시간):